Amnon Peled

Hebrew University of Jerusalem — Israel

Medicine · Health Sciences

54h-index13.5kcitations277works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemokine receptors and signaling(79), Immunotherapy and Immune Responses(56), Multiple Myeloma Research and Treatments(41), Immune Cell Function and Interaction(37), Pancreatic and Hepatic Oncology Research(26)

Publications277 total

DSP502 Combines Dual Inhibition of PD-L1 and PVR to Trigger Anticancer Immune Responses
Molecular Cancer Therapeutics·2026Open Access
Abstract A056: Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer
Cancer Research·2025
P-051 Antibodies in Seminal Fluid: A Potential Marker of Blood-Testis Barrier Integrity? A Prospective Clinical Trial
Human Reproduction·2025Open Access
FRI-064 MicroRNA-122 functions as a rheostat regulating liver tolerance, inflammation and fibrosis
Journal of Hepatology·2025
Abstract 6874: Bkt300, a novel small molecule targeting the protein regulator of cytokinesis 1 pathway in hepatocellular carcinoma
Cancer Research·2025Open Access
Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1
Frontiers in Immunology·2025· 1 citedOpen Access
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway
2025Open Access
SIL-204 siRNA encapsulated in extended release microparticles for the treatment of localized cancer that harbors a KRAS G12x or G13D mutation.
Journal of Clinical Oncology·2025· 1 cited
357 Skill-T: a safe and effective, off-the-shelf anti-cancer T-cell therapy
Regular and Young Investigator Award Abstracts·2024Open Access
WED-534 MiR122 expression regulates liver immune tolerance and microenvironment
Journal of Hepatology·2024
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies
Drug Safety·2024· 11 citedOpen Access
Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway
Cancer Research·2024
The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data
Cells·2024· 11 citedOpen Access
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis
JCI Insight·2023· 34 citedOpen Access
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
page 1 of 14Next →

Frequent Co-authors

Arnon Nagler(20), Eithan Galun(17), Ori Wald(17), Katia Beider(15), Hanna Wald(15), Tsvee Lapidot(13), Ido D. Weiss(12), Michal Abraham(11), Isabelle Petit(9), Órit Kollet(7), R. Alon(7), Eli Pikarsky(5), Orly Eizenberg(5), Tanya Ponomaryov(4), Dov Zipori(4), Nobutaka Fujii(4), Valentin Grabovsky(4), Jan A. Burger(4), Merav Darash‐Yahana(4), Evelyne Zeira(4)